
AQST Stock Forecast & Price Target
AQST Analyst Ratings
Bulls say
Aquestive Therapeutics Inc is positioned favorably in the specialty pharmaceutical market, particularly due to its focus on the no-needle epinephrine sector, which showcases a promising growth opportunity for oral and intranasal alternatives. The company's stock experienced a significant uptick of 43.77% following the FDA's decision not to require an Advisory Committee meeting for the New Drug Application (NDA) of Anaphylm, indicating strong investor confidence in its regulatory progress. The successful preparation of the data package for the NDA suggests that Aquestive is on a solid path towards potential approval, bolstering expectations for revenue growth from its innovative product offerings.
Bears say
Aquestive Therapeutics is facing significant financial risks, primarily due to the potential failure of the development of AQST-109, which could hinder future growth. Additionally, there are concerns regarding an anticipated decline in revenues from its licensed commercial products, impacting the company's overall financial stability. The necessity to raise capital further complicates Aquestive's financial outlook, indicating weaknesses in its balance sheet that could affect investor confidence.
This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
AQST Analyst Forecast & Price Prediction
Start investing in AQST
Order type
Buy in
Order amount
Est. shares
0 shares